About
Vision
Indigo provides an answer to the pressing need for accurate and affordable chronic disease management by providing innovative high-tech solutions for advanced biomarker sensing characterized by the best possible user experience and highest product quality.
Using its nanophotonics technology, Indigo is committed to lighting up the life of millions of people living with chronic disease through innovative medical technologies.
Mission
Our mission is to lighten up the lives of people living with chronic disease by enabling accurate continuous multi- metabolite monitoring to improve outcomes, lower costs and enhance quality of life.
The Company
Indigo is a pioneer of continuous multi-metabolite monitoring and was founded by Danaë Delbeke and her team in 2016.
Today, the company is developing a continuous multi-metabolite monitoring (CMM®) system for people living with chronic diseases to provide them with access to information on their metabolite levels at any time, without having to wear an external device on their body.
Indigo exploits ground-breaking nanophotonics technology, which was responsible for revolutionizing the Internet, to transform chronic disease management.
Indigo is headquartered in Ghent, Belgium and also has employees based in the US.
Indigo, the color
The color indigo owes its position in the color spectrum to Sir Isaac Newton, the 17th Century mathematician, physicist, astronomer and theologian, who established indigo as the 7th color.
Indigo is neither a primary nor a secondary color. The human eye is almost incapable of detecting indigo and it takes specific sensitivity to identify the color.
For reasons of perfection however, Newton added indigo to the set of six primary and secondary colors (red, orange, yellow, green, blue, violet) to have the spectrum in accordance with music (7 notes), the seven heavenly bodies (planets and sun and moon) known at the time, and the seven days of the week.
Indigo, the color of light that was missing from the spectrum, makes it perfect.
Indigo’s technology relies on light to accurately sense metabolites in the patient.
“We are delighted to be part of the further growth and development of Indigo as a long-term investor. The company boasts an excellent management team that has grown from a unique ecosystem that combines UGent’s photonics expertise with imec’s nanoelectronics expertise. We are convinced that Indigo’s sensor can initially make a substantial difference for people with diabetes and see a broader application potential for this mini-spectrometer going forward.”
Management
Danaë Delbeke
CEO and Founder
peter j. devlin
president
emmet lydon
chief operating officer
ILSE PENSAERT
VP HUMAN RESOURCES
Gijs Klarenbeek
VP Clinical and Medical Affairs
Daniel Verstappen
VP Quality and Regulatory Affairs
Scientific Advisory Board
DR. TADEJ BATTELINO
Head of Department of Endocrinology, Diabetes & Metabolism, Faculty of Medicine, University of Ljubljana, Slovenia
DR. ERIC RENARD
Head of Department of Endocrinology, Diabetes & Metabolism, Medical School, University of Montpellier, France
DR. THOMAS DANNE
Director of Department of General Pediatrics Endocrinology/Diabetology & Clinical Research, Hannover Medical School, Germany
DR. CHRISTOPHE DE BLOCK
Head of Department of Endocrinology, Diabetology and Metabolic Disease, University of Antwerp, Belgium
DR. MICHAEL C. RIDDELL
School of Kinesiology & Health Science, York University, Canada
DR. ANANDA BASU
Division of Endocrinology, University of Virginia, USA
DR. ANNE PETERS
Keck School of Medicine, University of Southern California, USA
Investors
Indigo has an international syndicate of highly respected investors, led by Fund+ and including Ackermans & Van Haaren, Thuja Capital, PMV, Capricorn Partners, imec.xpand, Qbic and private investors.
Partners
Indigo was founded by Danaë Delbeke and her team in 2016, as a spin-off of Ghent University and imec, Belgium’s global research centre, well known for its advances in the fields of nanoelectronics and digital technologies including silicon photonics.
Support
Indigo has received funding from the European Union’s Horizon 2020 Research And Innovation Programme under Grant Agreement No 811792.
Indigo is supported by Flanders Innovation and Entrepreneurship (Vlaio).
